Christina Mayer

Associate Director, Clinical Pharmacology, Integrated Drug Development

About Christina Mayer

Dr. Mayer joined Certara in June 2018 as Associate Director of Clinical Pharmacology in the Integrated Drug Development. Christina provides expertise in translational and early to mid-stage clinical development of oncology biologics, including traditional monoclonal antibodies as well as novel platforms/approaches such as engineered antibodies, bi-specifics, gene therapies, cell therapies, and combination therapies. 

Dr. Mayer’s experience includes NME to IND strategy, pre-IND NME risk assessment, non-clinical PK/PD and TK study design and analysis, justification of first-in-human dose, regimen, escalation strategy, maximum dose, flat dosing, and Phase 2 dose justification. She also has experience in NCA, sampling schemes, bioanalytical considerations, and analysis plans for PK, PD, receptor occupancy, and target engagement, Phase 1 in-stream evaluation of PK relationships with safety, efficacy, and PD, and multi drug combination study dose selection and trial design 

Dr. Mayer earned a BS degree from Boston College and PharmD with Honors from the University of North Carolina, Chapel Hill. She completed a postdoctoral fellowship in Clinical PK/PD at the University of North Carolina, Chapel Hill and GlaxoSmithKline. Prior to Certara, she worked as a Clinical Pharmacology Lead at Janssen Biotherapeutics (Johnson & Johnson).  Dr. Mayer is also a practicing pharmacist and an active lecturer in clinical pharmacology globally.